Brand Intelligence Graph
Company Overview
About EpiBiologics
EpiBiologics develops EpiTAC — a targeted protein degradation platform designed to eliminate membrane and secreted proteins that existing degrader technologies cannot reach. The company raised $107 million in Series B financing in January 2026, co-led by Johnson & Johnson Ventures and Google Ventures, a rare investor pairing that brings both pharma development expertise and computational biology capabilities. The lead program, EPI-326 (an EGFR degrader for non-small cell lung cancer), is entering Phase 1 clinical trials in the first half of 2026.
Business Model & Competitive Advantage
Targeted protein degradation (TPD) — using molecular glues and PROTACs to hijack the cell's own protein disposal machinery — has become one of oncology's most active drug discovery fields. However, the majority of current degraders can only reach intracellular targets: the proteins inside the cell. EpiBiologics' EpiTAC platform extends degradation to membrane-bound receptors (including growth factor receptors and immune checkpoints) and secreted proteins in the extracellular space — dramatically broadening the target class that degradation approaches can address.
Competitive Landscape 2025–2026
J&J Ventures' co-lead is particularly significant given Janssen's deep oncology portfolio and history of acquiring precision oncology assets: EpiBiologics' platform access to targets like EGFR — which has driven multiple Janssen-adjacent drug classes — signals potential strategic interest in both the technology and the clinical assets.
Key Differentiators
Emerging Innovator
EpiBiologics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Saluda Medical
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US oper
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Compare EpiBiologics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from EpiBiologics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim EpiBiologics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention EpiBiologics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →